AMPHION INNOVATIONS (LON:AMP)

SECTOR – HEALTHCARE

RATING – CORP*

MARKET CAP – £1.36m

CURRENT PRICE – 0.65p

ANALYST – LIAM GASCOIGNE-COHEN

Year-end Dec

2015A

2016A

2017A

2018E†

Revenue (US$m)

0.5

0.1

0.3

No

Forecasts

Operating loss (US$m)

(4.2)

(3.3)

(2.9)

Pre-tax Profit (US$m)

5.9

(16.8)

2.5

EPS (cents)

3

(9)

1

DPS (cents)

-

-

-

NAV (US$m)

10.9

(5.9)

(2.8)

P/E (x)

-

-

-

Dividend yield (%)

-

-

-

EV/EBITDA (x)

-

-

-

SOURCE: Northland Capital Partners Limited estimates. Priced at market close. *Northland Capital Partners Limited acts as Joint Broker to Amphion and therefore this information should be viewed as a Marketing Communication.

Partner Company, WellGen, Finalises License Agreement

NORTHLAND VIEW

• WellGen Inc., a nutraceutical company of which Amphion holds a 27% stake, has signed a license agreement with two Missouri-based beverage companies: Sportables LLC and One11 Innovation.
• WellGen will receive 11% of the profits derived from the commercial development and sale of Workout Tea™. WorkOut Tea™ a fitness beverage based on a patented and clinically proven anti-inflammatory ingredient derived from a black tea extract. It is sold in the US in a number of flavours.

WellGen is targeting the rapidly growing sports beverage market estimated to reach US$6bn by 2021 (2016 estimate: US$4.6b), according to OrbisResearch.com. Amphion’s other partner companies continue to make progress. Polarean Imaging (POLX.L) is in Phase 3 trials for its novel drug-device platform and Motif Bio (MTFB.L) is awaiting an FDA approval decision for its next generation antibiotic.

COMPANY DESCRIPTION

Amphion Innovations is an incubator of medical, life science, and technology businesses.